First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.

Jeeyun Lee,Seung Hoon Kim,Sujin Lee,Se Hoon Park,Joon Oh Park,Jeong-Won Lee,Kyoung-Mee Kim,Hukeun Lee,Sung Hong,Jung-Yong Kim,Song-Jae Lee,Seong-Won Song,Jung Ju Kim,Young Suk Park,Ho Yeong Lim,Won Ki Kang,Do-Hyun Nam

First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.

2018

Jeeyun Lee
Seung Hoon Kim
Sujin Lee
Se Hoon Park
Joon Oh Park
Jeong-Won Lee
Kyoung-Mee Kim
Hukeun Lee
Sung Hong
Jung-Yong Kim
Song-Jae Lee
Seong-Won Song
Jung Ju Kim
Young Suk Park
Ho Yeong Lim
Won Ki Kang
Do-Hyun Nam

e14501Background: The aim of this study was to determine the maximum tolerate dose (MTD), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of YYB101, a hepatocyte growth factor (HGF) neutra...

Keywords:

Antibody
Cancer research
Hepatocyte growth factor
Pathology
Medicine
solid tumor
first in human
Refractory
Pharmacodynamics
Pharmacokinetics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations